Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Critieria, Pathogenesis Highlight New Lupus Efforts

Natasha Yetman  |  August 22, 2018

Research on SLE
Researchers have discovered important details about the pathogenesis of lupus in recent years that could help lead to more effective therapy, said David Daikh, MD, PhD, president of the ACR and rheumatology chief at the San Francisco Veterans Affairs Medical Center.

In one set of recent findings, researchers showed that interferon-alpha enhances interleukin (IL) 6 production in neutrophils that are stimulated with a toll-like-receptor (TLR) 8 agonist. They also showed that neutrophils from lupus patients with active disease produced increased amounts of IL-6 and TNF-alpha in response to the TLR8 agonist.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Investigators also highlighted how neutrophil extracellular traps (NETs) contribute to a cycle of inflammation in lupus. NETosis—the cell death process that ends with the springing of these chromatin traps to entangle bacteria—relies on the oxidation of cells. Recently, researchers have shown that these NETs in lupus contain oxidized mitochondrial DNA, which induces inflammatory cytokines.2

Other research has found oxidative stress brings about clustering of mitochondrial antiviral signaling proteins, part of the innate immune defense against viruses, which drive interferon production. This finding raises the possibility of using anti-oxidant therapy for lupus, Dr. Daikh said.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Elsewhere, researchers recently identified three variants of the ITGAM gene, which encodes CD11b, that are linked with elevated levels of interferon in lupus. This finding suggests a direct link between CD11b activity and chronic inflammation in the disease.4

Little by little, these insights are revealing why the disease is so heterogeneous: There are many points at which the inflammatory process can malfunction. Dr. Daikh said these findings are taking lupus research in the right direction.

“As we think boldly, now, about lupus pathogenesis and where we should be putting our attention, we really have to focus on the downstream impacts of cellular activation,” Dr. Daikh said. “It’s very hard to prevent all infections. Our lupus patients will be confronted by various viral and bacterial infections, … and so we have to think downstream of those initial signals in terms of modulating activating signals in the adaptive response.

“The ultimate goal would be to be able to tailor specific targeted therapy with individuals who match the heterogeneity that we see—for example, patients who have impaired CD11b function—to provide an effective target for a subset of patients.”


Thomas R. Collins is a freelance writer living in South Florida.

References

  1. Zimmermann M, Arruda-Silva F, Bianchetto-Aguilera F, et al. IFNα enhances the production of IL-6 by human neutrophils activated via TLR8. Sci Rep. 2016 Jan 21;6:19674.
  2. Lood D, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016 Feb;22(2):146–153.
  3. Buskiewicz I, Montgomery T, Yasewicz E, et al. Reactive oxygen species induce virus-independent MAVS oligomerization in systemic lupus erythematosus. Sci Signal. 2016 Nov 29; 9(456):ra115.
  4. Faridi MH, Khan SQ, Zhao W, et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest. 2017 Apr 3;127(4):1271–1283.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Classification CriteriacriteriaPathogenesisResearchsystemic lupus erythematosus (SLE)

Related Articles

    Researchers Release Proposed Lupus Criteria, & Pathogenesis Findings

    September 20, 2018

    AMSTERDAM—Newly proposed systemic lupus erythematosus (SLE) classification criteria and new findings on SLE pathogenesis are two ways in which researchers and clinicians are getting a better grasp on the heterogeneous disease. The criteria and findings were discussed this June in a session at EULAR: the Annual European Congress of Rheumatology. ‘Paradigm Shift’ Sindhu Johnson, MD,…

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    2019 EULAR/ACR SLE Classification Criteria Offer Improved Sensitivity & Specificity

    November 6, 2019

    The new EULAR/ACR classification criteria for SLE offer improved sensitivity and specificity, as well as more accurately reflect the current tests used to clinically diagnose SLE. A positive ANA test is obligatory…

    More Info on the J&J COVID-19 Vaccine Thrombosis Scare

    May 13, 2021

    More than 7 million doses of the Johnson & Johnson single-dose vaccine have been administered in the U.S.1 On Apr. 23, the Centers for Disease Control & Prevention (CDC) and the U.S. Food & Drug Administration (FDA) recommended lifting the recommended pause on Johnson & Johnson COVID-19 vaccine use following a thorough safety review. 2…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences